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Abstract: This study aims to assess direct cost of reconstructive interventions with facial 
  fillers for treatment of HIV (human immunodeficiency virus)-associated facial lipoatrophy 
(FLA). Evaluation was performed on data from patients enrolled in one arm of a comparative 
study of immediate versus delayed reconstructive treatment of facial lipoatrophy. Median costs 
were standardized for efficacy, estimated using data reported by physicians and patient reported 
  outcomes. The variations of the results were evaluated with a sensitivity analysis. Evaluation was 
performed on 66 patients characterized by significant differences in terms of severity of FLA. 
Total cost resulted of €140,416.15, with a median cost per patient of €2126.04 (interquartile 
range [IQR]: 1599–2822). Taking into consideration severity of disease, median costs were 
€1641.67 (IQR: 1326.67–2126.04) and 2557.12 (IQR: 1939.34–2872.04) (P = 0.0) respectively 
for patients with low and high severity scores at baseline. Significant differences in term of 
cost-effectiveness ratios were also found between patients with different severity of FLA, and 
sensitivity analysis showed that these ratios increase with higher severity scores at baseline and 
vary widely depending on the costs of filler. Although these results cannot be considered rep-
resentative because of important limitations, the present study suggests the severity of disease 
as an important determinant of costs.
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Introduction
Lipodystrophic syndrome (LDS) is characterized by body fat alterations and meta-
bolic abnormalities1 and is a common and highly worrying long-term complication of 
people living with human immunodeficiency virus (HIV) infection taking highly active 
antiretroviral therapy (HAART). One of the most distressing expressions of LDS is 
facial lipoatrophy (FLA), defined as the loss of facial fat, including the buccal fat and 
temporal fat pads, which leads to facial skeletonization with concave cheeks, prominent 
nasolabial folds, periorbital hollowing, and visible facial musculature.2 Changes in body 
image may result in self-esteem reduction, poor adherence to therapeutic schedule, and 
social withdrawal due to the stigma related to disclosure of HIV-status.3 The poor knowl-
edge about pathogenesis and progression of LDS limits the implementation of therapeutic 
strategies to properly face its management.4 To date, poor results have been obtained with 
current therapeutic approaches. Drug switching from stavudine or zidovudine to abacavir 
or tenofovir provides only limited benefits, while change in life habits, such as diet or 
physical exercise, have almost no efficacy.5 Novel antidiabetic drugs, glitazones, cause 
little improvement in HAART-associated lipoatrophy, but increase blood cholesterol and 
triglyceride concentrations significantly, and thus cannot be recommended.6Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Some new approaches including uridine supplementation 
and use of adipocytokines, growth hormone, metformin, and 
statins (alone or in combination) merit further investigation.7 
Autologous fat transfer has been used successfully to improve 
the appearance in patients with FLA,8 but it is a more invasive 
surgical procedure than injections of facial fillers.
Interest in surgical interventions with facial fillers 
for correction of FLA has recently been growing, as they 
are minimally invasive and appear to give an immediate 
psychological relief to the patient.5 Among the commonly 
used facial fillers, encouraging results have been achieved 
with poly-L-lactic acid (PLA) (Sculptra® 2004),9 a biode-
gradable, synthetic polymer, and with polyacrylamide gel 
(PAIG) (Aquamid® 2005),10 an immunologically inactive, 
nonresorbable filler.
The present study aims to assess the monetary cost of 
the surgical correction of HIV-related FLA by injections 
with the abovementioned facial fillers using data from a 
clinical study.11
Methods
study design and aim
Evaluation was performed using data from one arm of a 
comparative open-label study of immediate versus delayed 
reconstructive treatment for antiretroviral-associated FLA with 
PLA or PAIG.11 For the present analysis, we only used data 
from the immediate treatment group (ITG) of such randomized 
open-label study. ITG patients were monitored for a 24-week 
period. Total costs to sustain the surgery correction were 
calculated for each patient and then standardized for efficacy 
expressed as reduction of FLA grade; subsequently, both costs 
and cost/efficacy ratios were calculated taking into account the 
severity scores at baseline. Based on severity score as reported 
by the surgeon, the population was divided into “low severity” 
(grade 1–3), and “high severity” (grade 4–5).
Patients
In the main study were enrolled patients with the follow-
ing inclusion criteria: 18 years of age or older; HIV-related 
LDS with moderate and severe FLA (evaluated by surgeon) 
and eligible for corrective surgical intervention on the basis 
of surgeon’s opinion; CD4 .100/mm3; HIV-RNA ,1000 
copies/mL; stable HAART for at least 6 months. Exclusion 
criteria included pregnancy, previous treatment with dermal 
fillers, current anticoagulant or cortisone treatments, AIDS 
dementia complex, unstable diabetes mellitus, skin diseases 
(such as herpes, psoriasis, and any dermatitis in active phase), 
dental treatments, no good clinical condition. All individuals 
eligible for FLA treatments were offered detailed descriptions 
of product characteristics, and the choice of filler was made 
according to experience of surgeon and patient’s preference. 
All the participants were enrolled by a single large Italian 
clinical center: the National Institute for Infectious Diseases 
“L. Spallanzani”, Rome, and a written informed consent was 
signed by each patient.
costs
Only direct costs were taken into consideration and were costs 
for surgeon, surgeon’s assistant, surgery supplies, and fillers. 
Cost of the surgeon was estimated considering the annual 
costs and total number of applications; costs of the assistant 
of the surgeon was calculated considering the annual costs 
and the time necessary to perform the intervention. Costs of 
disposable materials were computed considering the unit costs 
and the amount used during the clinical trial; costs of fillers 
were expressed taking into consideration total number of vials 
used. Costs of adverse events were not estimated because they 
resolved spontaneously without any therapeutic intervention 
(pharmacological or surgical). Evaluations have been con-
ducted from the service supplier’s perspective, and because of 
the short follow-up period, discounting was not applied.
effectiveness
The efficacy of facial fillers was expressed in terms of per-
centage of change, from baseline to the end of corrective 
intervention, of severity grade of FLA assessed by both 
physician and patient. The change in FLA grading score 
determined by the physician was estimated using a validated 
FLA severity scale, which ranged from grade 1 (mild lipoat-
rophy) to grade 5 (the most severe lipoatrophy).12
The change in FLA grading score as determined by the 
patient was evaluated using a severity scale, which provides 
standardized scores: none (0), mild (1), moderate (2), and 
severe (3).13
Dermal fillers for lipoatrophy correction
Dermal fillers used were PAIG (Aquamid®, Contura, 
  Soeberg, Denmark) and PLA (Sculptra®, Aventis Pharma-
ceutical, Collegeville, PA) dermal fillers.
PAIG is an injectable hydrogel implant composed 
of 97.5% apyrogenic water bound to 2.5% cross-linked 
polyacrylamide. It is a permanent filler and is nonresorb-
able, nonallergenic, physically and chemically stable, 
and immunologically inactive. It is available in two vari-
ants Aquamid and Aquamid Reconstruction (made with 
higher viscosity for treatments that require more volume), Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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both in 1 mL pre-filled syringes.14 Sculptra® (PLA) is an 
  injectable implant and contains microparticles of poly-L-lactic 
acid, a biocompatible, biodegradable, synthetic polymer 
from the alpha-hydroxy-acid family. It is reconstituted at 
least 2 hours prior to use by the addition of 4–6 mL of sterile 
water for injection to form a sterile suspension. PLA works to 
stimulate a progressive increase in dermal thickness.15
Patients received a set of 2–5 injections, with a 4-week 
period between two injections. At each surgery session, the 
specific facial morphologic features of the patients were care-
fully analyzed before the injection of fillers, and color digital 
photographs were collected before and after each injection 
session. Neither prophylactic antibiotics nor local anesthesia 
was administered preoperatively. At each injection session, 
patients received several injections into and around the deep 
dermis of the atrophied perimalar area. The injected quantity 
of material depended on the severity of skin depression. 
The treatment was discontinued if any adverse reaction had 
occurred following the injection.
Data collection
Study entry demographic data included gender, age, and 
route of transmission. Baseline clinical information included 
duration of HIV disease, HIV disease stage (Centers for Dis-
ease Control and Prevention [CDC]), HIV RNA viral load, 
CD4+ cell count, and years of previous antiretroviral therapy 
(ART). FLA severity grades were collected at baseline and 
at the end of the treatment.
statistical analysis
Baseline characteristics of demographic and clinical variables 
were reported; median costs were calculated and then standard-
ized for efficacy and reported for both surgeons and patients.
A sensitivity analysis was performed using a linear 
regression model in order to explore the changes of the result-
ing cost efficacy (C/E) ratios when varying the cost of fillers 
and severity scores at baseline. Cost of fillers and severity 
scores at baseline were the independent variables introduced 
in the linear regression model, which in a   preliminary 
Table 1 Baseline characteristics
All Low severity High severity P-value
n 66 29 37
Sex 
Male n (%) 56 (84.8) 21 35 0.017a
Age
Mean ± sD 44.48 ± 5.8 43.41 ± 5.481 45.32 ± 5.991 0.58b
Median (iQr) 43.00 (42–47) 43.00 (40.0–46.5) 43.00 (42.0–48.5)
Risk factor n (%)
homosexual 26 (33.3) 12 14 0.904a
Drug user 18 (39.4) 7 11
heterosexual 22 (27.3) 10 12
CD4
Mean ± sD 663.53 ± 320.874 707.03 ± 333.331 629.43 ± 311.067 0.629b
Median (iQr) 602.50 (437.75–799.50) 626.00 (445.5–849.5) 565.00 (403.5–737.0)
HIV RNA (log)
Mean ± sD 1.9677 ± 69354 1.8519 ± 0.53101 2.0584 ± 9367 0.38b
Median (iQr) 1.69 (1.69–1.69) 1.69 (1.69–1.69) 1.69 (1.69–1.86)
Stage n (%)
cDc A 6.00 (9.10) 4 2 0.737a
cDc B 36.00 (54.6) 16 20
cDc c 24.00 (36.4) 9 15
Time from HIV diagnosis (years)
Mean ± Ds 12.86 ± 4.917 12.72 ± 4.165 12.97 ± 5.490 0.126b
Median (iQr) 12.00 (10.00–15.25) 12.00 (10.5–15.5) 12.00 (9.5–16.5)
Time from lipodystrophy syndrome
Mean ± sD 5.14 ± 2.259 5.00 ± 2.171 5.24 ± 2.350 0.742b
Median (iQr) 5.00 (3.00–6.25) 5.00 (3.0–6.5) 5.00 (3.0–6.5)
Years on ART
Mean ± sD 9.45 ± 2.943 9.33 ± 2.707 9.55 ± 3.149 0.606b
Median (iQr) 10.00 (7.875–10.250) 10.00 (7.5–10.5) 10.00 (7.75–10.5)
Notes: aχ2 test; bstudent’s t-test. 
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention stage; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, 
ribonucleic acid; sD, standard deviation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 3 Cost and utilization of fillers
All PAIG PLA P-valuea
N of fillers 531 296b 235
Median fillers (IQR) 8.0 (6–10) 9.5 (7.75–10) 7.0 (6–9) 0.03
Total costs of filler 128742.45 79392.45 49350.00
Median cost of filler 
(iQr) min–max
1890(1417–2650.5) 2517.97(2054.13–2710.35) 
795.15–3790.00
1470.00 (1260–1890) 
840.0–2730.0
0.00
Notes: cost is in euros. aMann–Whitney test; b296 = Aquamid 249 and AquamidR = 47. 
Abbreviations: IQR, interquartile range; PAIG, polyacrylamide gel; PLA, poly-L-lactic acid.
Table 2 Facial lipoatrophy severity score at baseline
Surgeon reported Patient reported
grade 2 10 38
grade 3 19 28
grade 4 31
grade 5 6
  univariate analysis showed significant correlations with C/E 
ratios (calculated using efficacy data reported by surgeons) 
as dependent variables.
The variations of independent variables was ±20% for 
filler costs and grade 1 and grade 5 for severity scores at 
baseline. Cost of care technique was used to evaluate short-
term costs of surgical correction of FLA.
Results
Baseline characteristics
Analysis was conducted on 66 of 67 patients that were included 
in the ITG arm of the main clinical trial. In this population, 
mean time from HIV diagnosis was 12.9 ± 4.9 years, mean 
time from lipodystrophy syndrome 5.1 ± 2.3 years, and mean 
time on ART was 9.4 ± 2.9 years (Tables 1 and 2).
Efficacy
The patients enrolled received an average of four filler appli-
cations (range 2–5) over a mean period of 21 weeks (range 
7–55). Changes from baseline to the end of surgical interven-
tion were different depending on the evaluation performed 
by physicians or patients. Physicians reported a mean change 
of 86.38 ± 20.34 and a median change of 100 (interquartile 
range [IQR]: 75–100). Patient-reported evaluation showed 
a mean change of 79.38 ± 31.23, while the median change 
was 100 (IQR: 50–100) (data not shown).
costs and cost-effectiveness
Total cost to sustain the FLA treatments for 66 patients was 
€140,416.15, with a median cost for patients of €2126.04 
(IQR: 1599.90–2822.17).
Total cost of surgeon for 272 applications (PAIG = 134 
and PLA = 138) was €9000; cost of assistant of surgeon 
was €1846.88, considering a mean time of 30 minutes for 
intervention. Costs and number of fillers for PAIG were sig-
nificantly higher than PLA (Table 3). After stratification for 
severity of disease, resulting total median costs were signifi-
cantly   different; for patients with low severity score at base-
line, median costs were €1641.67 (IQR: 1326.67–2126.04); 
median costs of patients with high severity of disease were 
€2557.12 (IQR: 1939.34–2872.04). Median C/E ratios 
based on efficacy reported by physicians were €17.19 (IQR: 
13.26–25.00) and €28.82 (IQR: 23.23–37.62) respectively for 
low and high severity scores. When efficacy was calculated 
on data reported by patients, resulting median C/E ratios were 
23.57 (IQR: 14.53–33.60) and 31.47 (IQR: 23.03–41.19) 
respectively for low and high severity scores (Table 4).
sensitivity analysis
Nonstandardized coefficients of the linear regression model were 
β1 = 0.011 for cost of fillers, β2 = 5.537 for lipodystrophy sever-
ity scale at baseline, with a constant value of -11.918. When 
baseline severity score was grade 1, the resulting C/E ratios were 
€10.25 and €18.56; C/E ratios of €32.39 and €40.73 were 
found when the severity at baseline was grade 5.
Discussion and conclusion
FLA is a long-term toxicity associated with HAART for treat-
ment of people with HIV infection, and corrective interven-
tions with facial fillers for HIV-associated FLA represent an 
important approach to treat this clinical condition. This study 
aims to assess direct costs of reconstructive surgery.
C/E ratios increase with higher grade of FLA and 
vary widely depending on the costs of fillers as showed 
by sensitivity analysis; these results cannot be considered 
representative of all people with HIV infection affected by 
FLA because the sample size is not large enough; another 
limitation is the subjective assessment of FLA other than 
the short follow-up. Despite these limitations, the suggestion Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 4 cost and c/e ratios
All Low severity High severity P-valuea
Total cost 140,416 50,469.76 89,946.39 0.00
Cost
Median (iQr) 2126.04 (1599.90–2822.17) 1641.67 (1326.67–2126.04) 2557.12 (1939.34–2872.04) 0.00
C/E ratio (physician)
Median (iQr) 25.13 (16.41–32.83) 17.19 (13.26–25.00) 28.82 (23.23–37.62) 0.00
C/E ratio (patient)
Median (iQr) 28.62 (18.50–38.80) 23.57 (14.53–33.60) 31.47 (23.03–41.19) 0.03
Notes: cost is in euros. aMann–Whitney test. 
Abbreviations: C/E, cost/efficacy; IQR, interquartile range.
of severity of disease is consistent with data from another 
study, where association between lipodystrophy assessment 
score with health care costs and utilization was observed,16 
showing lipodystrophy severity as an important predictor 
of health care expenditures. The observational period of 
24 weeks doesn’t permit to estimate the costs completely 
because of retreatments caused by durability of the correc-
tions. The persistency of efficacy determining the aesthetic 
benefits and thus the number of applications and of fillers 
could change the economic weight of these interventions. 
Differences in the persistency of efficacy depend on the 
nature of the fillers;17 the use of biodegradable products, 
like PLA, is usually limited by their short durability while 
nonbiodegradable fillers, like PAIG18 are characterized by 
prolonged permanence. Although the surgical correction 
of FLA doesn’t invariably result in a positive impact on 
psychosocial wellbeing and on health related quality of 
life,11 it determines a clinical improvement of FLA severity 
as reported by both physician and patient. Patient-reported 
outcomes reflect the patient’s own perception of the improve-
ment, thus expressing a positive effect as supported by results 
on patient satisfaction reported in the literature.19
The heterogeneity and complexity of this clinical condi-
tion require a multidisciplinary approach. In this scenario, an 
important role is played by evaluation of costs also because 
this type of intervention is not assured by national health 
services. Our contribution consists of describing cost and 
C/E ratios, suggesting the “severity score” is a determinant 
of cost of these interventions. To date, few data on costs are 
available, so further studies with more adequate sample sizes, 
and longer observational periods, need to be implemented 
to improve the knowledge of the pharmacoeconomics of 
FLA corrective interventions. Such surgical procedures may 
open promising perspectives to face lipodystrophy in the 
management of HIV-infection, providing policy makers with 
an additional tool to properly address, also in terms of costs, 
the effects of this serious complication of ART.
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